Buspirone maintenance does not alter the reinforcing, subjective, and cardiovascular effects of intranasal methamphetamine.
Sign Up to like & getrecommendations! Published in 2017 at "Drug and alcohol dependence"
DOI: 10.1016/j.drugalcdep.2017.08.038
Abstract: BACKGROUND Medications development efforts for methamphetamine-use disorder have targeted central monoamines because these systems are directly involved in the effects of methamphetamine. Buspirone is a dopamine autoreceptor and D3 receptor antagonist and partial agonist at… read more here.
Keywords: methamphetamine use; intranasal methamphetamine; maintenance; buspirone maintenance ... See more keywords
A double-blind, randomized, placebo-controlled, pilot clinical trial examining buspirone as an adjunctive medication during buprenorphine-assisted supervised opioid withdrawal.
Sign Up to like & getrecommendations! Published in 2022 at "Experimental and clinical psychopharmacology"
DOI: 10.1037/pha0000550
Abstract: Successful management of opioid withdrawal improves long-term treatment outcomes and reduces opioid use-related morbidity and mortality. Mechanistically supported pharmacotherapeutic approaches are needed to effectively manage acute and protracted opioid withdrawal. Buspirone is a D2 antagonist… read more here.
Keywords: supervised opioid; withdrawal; double blind; buspirone ... See more keywords
A Retrospective Chart Review of Buspirone for the Treatment of Anxiety in Psychiatrically Referred Youth with High-Functioning Autism Spectrum Disorder.
Sign Up to like & getrecommendations! Published in 2019 at "Journal of child and adolescent psychopharmacology"
DOI: 10.1089/cap.2018.0021
Abstract: OBJECTIVES Anxiety disorders (ADs) are commonly associated with high-functioning Autism Spectrum Disorder (HF-ASD) and often worsen with age. Buspirone is a commonly prescribed anxiolytic drug with a favorable tolerability profile that may offer potential benefits… read more here.
Keywords: anxiety; treatment; high functioning; buspirone ... See more keywords
6‐Hydroxydopamine lesion and levodopa treatment modify the effect of buspirone in the substantia nigra pars reticulata
Sign Up to like & getrecommendations! Published in 2020 at "British Journal of Pharmacology"
DOI: 10.1111/bph.15145
Abstract: l‐DOPA‐induced dyskinesia (LID) is considered a major complication in the treatment of Parkinson's disease (PD). Buspirone (5‐HT1A partial agonist) have shown promising results in the treatment of PD and LID, however no 5‐HT‐based treatment has… read more here.
Keywords: nigra pars; pars reticulata; treatment; substantia nigra ... See more keywords
Inhibition of Axitinib on Buspirone Metabolism in vitro and in vivo
Sign Up to like & getrecommendations! Published in 2022 at "Drug Design, Development and Therapy"
DOI: 10.2147/dddt.s359451
Abstract: Objective To evaluate the effect of axitinib on buspirone metabolism in vitro and in vivo. Methods A microsome incubation assay was performed to study the effect and mechanism of axitinib on buspirone metabolizing. In vivo,… read more here.
Keywords: vitro vivo; buspirone metabolism; axitinib buspirone; buspirone ... See more keywords
Motor cortico-nigral and cortico-entopeduncular information transmission and its modulation by buspirone in control and after dopaminergic denervation
Sign Up to like & getrecommendations! Published in 2022 at "Frontiers in Pharmacology"
DOI: 10.3389/fphar.2022.953652
Abstract: Cortical information is transferred to the substantia nigra pars reticulata (SNr) and the entopeduncular nucleus (EP), the output structures of the basal ganglia (BG), through three different pathways: the hyperdirect trans-subthalamic and the direct and… read more here.
Keywords: information; ht1a; transmission; buspirone ... See more keywords
The Anxiolytic Drug Buspirone Prevents Rotenone-Induced Toxicity in a Mouse Model of Parkinson’s Disease
Sign Up to like & getrecommendations! Published in 2022 at "International Journal of Molecular Sciences"
DOI: 10.3390/ijms23031845
Abstract: A pharmacological and genetic blockade of the dopamine D3 receptor (D3R) has shown to be neuroprotective in models of Parkinson’s disease (PD). The anxiolytic drug buspirone, a serotonin receptor 1A agonist, also functions as a… read more here.
Keywords: parkinson disease; anxiolytic drug; buspirone; drug buspirone ... See more keywords